Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

This study has been completed.
Information provided by (Responsible Party):
Shire Identifier:
First received: November 19, 2012
Last updated: April 16, 2014
Last verified: April 2014
The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.

Condition Intervention Phase
Hepatic Impairment
Drug: SSP-004184
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects

Further study details as provided by Shire:

Primary Outcome Measures:
  • Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  • Maximum Plasma Concentration (Cmax) of SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

  • Time of Maximum Plasma Concentration (Tmax) for SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

  • Plasma Half-Life (T 1/2) of SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    The time it takes for the blood plasma concentration of a substance to halve.

  • Total Body Clearance (CL/F) of SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    The rate at which a drug is removed from the body.

  • Volume of Distribution (Vz/F) of SSP-004184 [ Time Frame: Over 96 hours post-dose ]
    The distribution of a medication between plasma and the rest of the body.

Enrollment: 44
Study Start Date: December 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SSP-004184 (Child-Pugh A Liver Impaired)
The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
Drug: SSP-004184
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other Name: SPD602, FBS0701
Experimental: SSP-004184 (Child-Pugh B Liver Impaired) Drug: SSP-004184
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other Name: SPD602, FBS0701
Experimental: SSP-004184 (Child-Pugh C Liver Impaired) Drug: SSP-004184
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other Name: SPD602, FBS0701
Experimental: SSP-004184 (Matched Healthy Subjects) Drug: SSP-004184
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Other Name: SPD602, FBS0701


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-65 years inclusive at the time of consent.
  • Willingness to comply with any applicable contraceptive requirements of the protocol and is:
  • Male, or
  • Non pregnant, non lactating female
  • Females must be at least 90 days post partum or nulliparous.

Subjects who do not have hepatic impairment (healthy subjects)

  • Normal renal function.

Subjects with hepatic impairment

  • Subjects must provide a letter of evaluation from a hepatologist or copy of supporting documents confirming the subject's hepatic impairment (a liver biopsy is preferable but not mandatory).
  • Hepatic impairment should be primary and must not be a complication of an underlying primary systemic disease (eg, patients with metastatic cancer and cancer cachexia)
  • Documented chronic stable liver impairment

Exclusion Criteria

Subjects who do not have hepatic impairment (healthy subjects)

  • A positive HIV antibody screen, Hepatitis B surface antigen, or Hepatitis C virus antibody screen.

Subjects with hepatic impairment

  • Presence of a hepatocellular carcinoma, or an acute hepatic disease caused by an infection or drug toxicity.
  • Presence of surgically created or transjugular intrahepatic portal systemic shunts.
  • A positive HIV antibody screen.
  • Renal insufficiency.

All subjects

  • Subject has a history of thyroid disorder.
  • History of nephrotic syndrome.
  • History of alcohol or other substance abuse within the last year.
  • A positive screen for alcohol or drugs of abuse.
  • Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day. (1 alcohol unit = 1 beer [12 oz/355 mL] = 1 wine [5 oz/150 mL] = 1 liquor [1.5 oz/40 mL] = 0.75 oz/20 mL alcohol.)
  • Caffeine consumption: For healthy subjects: Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches or have a history of caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz/180 mL cup of coffee, two 12 oz/355 mL (ie, 24 oz/710 mL cola) cans of cola, one 12 oz/355 mL cup of tea, three 1 oz/28 g chocolate bars (ie, 3 oz/85 g chocolate). Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
  • Donation of blood or blood products within 60 days.
  • Substantial changes in eating habits within 30 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01732263

United States, Florida
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014
Orlando Clinical Research Center (OCRC)
Orlando, Florida, United States, 32809
Sponsors and Collaborators
Principal Investigator: Kenneth Lasseter, MD Clinical Pharmacology of Miami
  More Information

Responsible Party: Shire Identifier: NCT01732263     History of Changes
Other Study ID Numbers: SPD602-105
Study First Received: November 19, 2012
Results First Received: April 16, 2014
Last Updated: April 16, 2014

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases processed this record on May 23, 2017